Replies to post #483757 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Then come out and say it. Just a few weeks ago he had that chance with the earnings call. He said nothing. Either hit the dates that you say or tell us why you missed.

It is inconceivable, after all the missed/inaccurate investor guidance over many years, that anyone would not agree that AVXL's low stock price is at least somewhat attributable to Missling's failure to provide meaningful and timely guidance regarding drug/trial timelines. I continue to grade him an F in this regard. The sad and unimpressive truth is that he seems to not realize (or perhaps he just doesn't give a damn) that accurate shareholder guidance and related timely execution is one of the keys to executive management credibility. Once a CEO loses credibility, that loss of credibility tends to extend/apply to all aspects/undertakings of a company.

[boi568]

Anavex does not control all the elements of timing, and if that one element that I think has gone missing, I don't see how Missling could say anything that would improve the situation.

[kund]

There is no new trial starting—Buffoon misspoke about the PD trial at JPM. Most of the time, he doesn’t even understand what he’s talking about. At JPM, he couldn't clearly articulate the company's achievements in simple words; EMA submission and peer review, he fumbled, struggling to find the words to complete his sentence. All PRs has some or other problem, no clarity is the biggest issue with his management style. The market has zero trust in his leadership, which is clearly reflected in the share price.